Form 4: Denali Therapeutics Director Jennifer Cook Reports Significant Equity Grant

Denali Therapeutics Inc. Director Jennifer E. Cook reported the acquisition of 6,037 Restricted Stock Units and 18,111 stock options on June 3, 2025, as part of her compensation package.

Summary

• Jennifer E. Cook, a Director of Denali Therapeutics Inc. (DNLI), acquired 6,037 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 3, 2025.
• These RSUs were granted at a price of $0 per share, indicating they are part of an equity compensation plan.
• The RSUs are contingent rights to receive one share of common stock and will vest upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Following this transaction, Jennifer E. Cook beneficially owns 26,075 shares of Common Stock, which includes the 6,037 unvested RSUs.
• Additionally, Ms. Cook acquired 18,111 stock options with an exercise price of $13.93 per share on June 3, 2025.
• These stock options were also granted at a price of $0, indicating they are part of an equity compensation plan.
• The options are exercisable as of June 3, 2025, and have an expiration date of June 3, 2035.
• The shares subject to the option will vest upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Following this transaction, Ms. Cook beneficially owns 18,111 stock options.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is a positive for aligning interests but does not provide new information on company performance or strategic direction. It's a routine disclosure.

Positives

• The grant of Restricted Stock Units and stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining experienced board members in the biotechnology industry.

Future Outlook

The vesting schedules for both the Restricted Stock Units and stock options indicate that they will vest upon the earlier of the one-year anniversary of the grant date (June 3, 2026) or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. This aligns the director's long-term interest with the company's future performance.

Industry Context

The grant of equity compensation, such as RSUs and stock options, to directors is a common and widely accepted practice across the biotechnology and pharmaceutical industries. It serves to align the interests of the board with those of the shareholders and is a key component of executive and director compensation packages designed to attract and retain top talent.

Comparison to Industry Standards

• The structure of this equity grant, including the use of RSUs and stock options with vesting conditions tied to time or the next annual meeting, is consistent with standard compensation practices for non-employee directors in publicly traded biotechnology companies.
• While specific comparable companies or projects are not detailed in this Form 4, similar compensation structures are observed at peers like Biogen Inc., Gilead Sciences, Inc., and Amgen Inc., where director compensation often includes a mix of cash and equity awards to foster long-term commitment and performance alignment.

Corporate Governance

Related Party Transactions

• The acquisition of 6,037 Restricted Stock Units and 18,111 stock options by Jennifer E. Cook, a Director of Denali Therapeutics Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to more shareholder-friendly decisions and long-term value creation.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Vesting of 6,037 Restricted Stock Units upon the earlier of June 3, 2026, or the day preceding Denali Therapeutics' next annual meeting of stockholders.
• Vesting of 18,111 stock options upon the earlier of June 3, 2026, or the day preceding Denali Therapeutics' next annual meeting of stockholders.
• Potential exercise of stock options by Jennifer E. Cook at an exercise price of $13.93 per share, anytime between June 3, 2025, and June 3, 2035, after vesting.

Key Dates

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Option, Equity Compensation, Director Compensation, Beneficial Ownership